140 related articles for article (PubMed ID: 32241206)
1. Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study.
Wang J; Jiang PF; Liu M; Kou MR; Lei JY; Yu XT; Zhao Y; Wang H; Zhang LN
J Int Med Res; 2020 Apr; 48(4):300060519893176. PubMed ID: 32241206
[TBL] [Abstract][Full Text] [Related]
2. Quantification of Diabetic Retinopathy Lesions in DME Patients With Intravitreal Conbercept Treatment Using Deep Learning.
Yu Q; Wang F; Zhou L; Yang J; Liu K; Xu X
Ophthalmic Surg Lasers Imaging Retina; 2020 Feb; 51(2):95-100. PubMed ID: 32084282
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
4. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy.
Ren X; Bu S; Zhang X; Jiang Y; Tan L; Zhang H; Li X
Eye (Lond); 2019 Jul; 33(7):1177-1183. PubMed ID: 30872770
[TBL] [Abstract][Full Text] [Related]
6. [Dexamethasone intravitreal implant (Ozurdex) in patients with diabetic macular edema: Real life safety and efficacy].
Majstruk L; Qu-Knafo L; Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
J Fr Ophtalmol; 2020 Mar; 43(3):197-204. PubMed ID: 32000989
[TBL] [Abstract][Full Text] [Related]
7. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.
Su L; Ren X; Wei H; Zhao L; Zhang X; Liu J; Su C; Tan L; Li X
Retina; 2016 May; 36(5):938-43. PubMed ID: 26630313
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy.
Mason JO; Yunker JJ; Vail R; McGwin G
Retina; 2008 Oct; 28(9):1319-24. PubMed ID: 18667958
[TBL] [Abstract][Full Text] [Related]
10. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
Jiang T; Gu J; Zhang P; Chen W; Chang Q
BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
[TBL] [Abstract][Full Text] [Related]
11. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
[TBL] [Abstract][Full Text] [Related]
12. The transient efficacy of a single intravitreal triamcinolone acetonide injection for diabetic macular edema.
Desatnik H; Habot-Wilner Z; Alhalel A; Moroz I; Glovinsky J; Moisseiev J
Isr Med Assoc J; 2006 Jun; 8(6):383-7. PubMed ID: 16833165
[TBL] [Abstract][Full Text] [Related]
13. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone.
Larsson J; Zhu M; Sutter F; Gillies MC
Am J Ophthalmol; 2005 May; 139(5):802-6. PubMed ID: 15860283
[TBL] [Abstract][Full Text] [Related]
14. Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections.
Zhang X; Wu C; Zhou LJ; Dai RP
Sci Rep; 2018 Mar; 8(1):3972. PubMed ID: 29507304
[TBL] [Abstract][Full Text] [Related]
15. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates.
Khairallah M; Zeghidi H; Ladjimi A; Yahia SB; Attia S; Zaouali S; Messaoud R
Retina; 2005; 25(7):835-9. PubMed ID: 16205560
[TBL] [Abstract][Full Text] [Related]
16. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection.
Zhang X; Wu J; Wu C; Bian AL; Geng S; Dai RP
Diabetes Res Clin Pract; 2020 Apr; 162():108083. PubMed ID: 32057965
[TBL] [Abstract][Full Text] [Related]
17. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
20. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy.
Lu Q; Lu L; Chen B; Chen W; Lu P
Can J Ophthalmol; 2019 Jun; 54(3):291-296. PubMed ID: 31109466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
